<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>Shining the Light on Aurora-A Kinase as a Drug Target in Pancreatic Cancer</td>
<td>David J. Bearss</td>
</tr>
<tr>
<td>2013</td>
<td>First Report of Functional Chk1 siRNA Studies Applied to Drug Discovery</td>
<td>Zehan Chen</td>
</tr>
<tr>
<td>2015</td>
<td>The Discovery and Development of SU14813, a Next-Generation Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Human Malignancies</td>
<td>Dana Hu-Lowe, Nicoletta Brega, and Shem Patyna</td>
</tr>
<tr>
<td>2016</td>
<td>PI3K Inhibitors for Cancer Treatment: Five Years of Preclinical and Clinical Research after BEZ235</td>
<td>Sauveur-Michel Maira</td>
</tr>
<tr>
<td>2017</td>
<td>Discovering and Developing PI3 Kinase Inhibitors for Cancer: Rapid Progress through Academic-Biotech-Pharma Interactions</td>
<td>Florence I. Raynaud and Paul Workman</td>
</tr>
<tr>
<td>2019</td>
<td>The Discovery of Lapatinib (GW572016)</td>
<td>David Rusnak and Tona M. Gilmer</td>
</tr>
<tr>
<td>2020</td>
<td>Methylation Profiling of Lung Cancer: A Decade of Progress</td>
<td>Shinichi Toyooka and Adi F. Gazdar</td>
</tr>
<tr>
<td>2021</td>
<td>MicroRNAs in Cancer Pharmacology and Therapeutics: Exploiting a Natural Synergy between ‘-omic’ and Hypothesis-Driven Research</td>
<td>John N. Weinstein</td>
</tr>
<tr>
<td>2022</td>
<td>Development of the First Generation c-Met Kinase Inhibitors: Beginning of a Path to a New Treatment for Cancer</td>
<td>Xueyan Wang, Gerald McMahon, and Kenneth E. Lipson</td>
</tr>
</tbody>
</table>
THERAPEUTIC DISCOVERY

Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Krüppel-like Factor 5 Expression by Ultrahigh-Throughput Screening
Agnieszka B. Białkowska, Melissa Crisp, Thomas Bannister, Yuanjun He, Sarwat Chowdhury, Stephan Schürer, Peter Chase, Timothy Spicer, Franck Madoux, Chenli Tian, Peter Hodder, Daniel Zaharevitz, and Vincent W. Yang

Discovery and Evaluation of Inhibitors of Human Ceramidase
Jeremiah M. Draper, Zuping Xia, Ryan A. Smith, Yan Zhuang, Wenxue Wang, and Charles D. Smith

Targeting the Intracellular MUC1 C-terminal Domain Inhibits Proliferation and Estrogen Receptor Transcriptional Activity in Lung Adenocarcinoma Cells
Carolyn M. Klinge, Brandie N. Radde, Yoannis Imbert-Fernandez, Yun Teng, Margarita M. Ivanova, Sabra M. Abner, and Alexandra L. Martin

A6 Peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation, and Inhibits the Migration and Metastasis of CD44-Expressing Cells
Randolph S. Piotrowicz, Bassam B. Damaj, Mohamed Hachicha, Francesca Incardona, Stephen B. Howell, and Malcolm Finlayson

PRECLINICAL DEVELOPMENT

Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways
Laura S. Angelo, Ji Yuan Wu, Feng Meng, Michael Sun, Scott Kopetz, Ian E. McCutcheon, John M. Slopis, and Razelle Kurzrock

Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells
Daina Z. Ewton, Jing Hu, Maria Vilenchik, Xiaobing Deng, Kin-chun Luk, Ann Polonskaia, Ann F. Hoffman, Karen Zipf, John F. Boylan, and Eileen A. Friedman

The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells

Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment

3,5-Bis(2,4-Difluorobenzylidene)-4-piperidone, a Novel Compound That Affects Pancreatic Cancer Growth and Angiogenesis
Dharmalingam Subramaniam, Nathan D. Nichols, Animesh Dhar, Shahid Umar, Vibhudutta Awasthi, Danny R. Welch, Roy A. Jensen, and Shrikant Anant

Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer
Johannes Taeger, Christian Moser, Claas Hellerbrand, Maria E. Mycielska, Gabriel Glockzin, Hans J. Schlit, Edward K. Geissler, Oliver Stoldtzing, and Sven A. Lang
MOLECULAR MEDICINE IN PRACTICE

Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization
Timothy Meier, Mark Uhlik, Sudhakar Chintharlapalli, Michele Dowless, Robert Van Horn, Julie Stewart, Wayne Blosser, James Cook, Debra Young, Xiang Ye, Glenn Evans, Kelly Credille, Darryl Ballard, Lysiane Huber, Andrew Capen, Marcio Chedid, Robert Ilaria, Jr., Micheele C. Smith, and Louis Stancato

Antitumoral Effects of Calcitriol in Basal Cell Carcinomas Involve Inhibition of Hedgehog Signaling and Induction of Vitamin D Receptor Signaling and Differentiation
Anja Uhmann, Hannah Niemann, Béreïnice Lammering, Cornelia Henkel, Ina Hoß, Frauke Nitzki, Anne Fritsch, Nicole Prüfer, Albert Rosenberger, Christian Dullin, Anke Schraepler, Julia Reifenberger, Stefan Schweyer, Torsten Fietisch, Frank Strutz, Walter Schulz-Schaeffer, and Heidi Hahn

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
Genshi Zhao, Wei-ying Li, Daohong Chen, James R. Henry, Hong-Yu Li, Zhaoen Chen, Mohammad Zia-Ebrahimi, Laura Bloem, Yan Zhai, Karen Huss, Sheng-bin Peng, and Denis J. McCann

ABOUT THE COVER

Met kinase homology model with its inhibitor, SU11271, docked in the ATP binding site. The cover image was selected from an article previously published in Molecular Cancer Therapeutics, which was chosen in celebration of the 10th anniversary of the journal. For details, see the commentary by Wang and colleagues on page 2022.

Correction: Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
